A new agreement with Novo Nordisk highlights unique positioning in GLP-1 implant development, with clinical trials for a semaglutide implant set to begin in August. The technology aims to improve adherence, convenience, and long-term outcomes in obesity treatment.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.